CINAMOPS: Critical Illness Polyneuropathy and Myopathy: Outcome, Predictors and Longitudinal Trajectories. A cohort study.

Conditions

G62.80 G72.80

Egger M, Finsterhölzl M, Wippenbeck F, Müller F, Jahn K, Huge V, Bergmann J.

2025-12-06

10.1016/j.jcrc.2025.155396

Long-term recovery of sensorimotor functions and prediction of participation in survivors of critical illness: a prospective cohort study

Johanna Weghorn, Melanie Finsterhölzl, Franziska Wippenbeck, Klaus Jahn, Marion Egger et al. (6 authors)

Journal of Intensive Care2025-09-081 citations

10.1186/s40560-025-00808-9

Comprehensive assessment and progression of health status during neurorehabilitation in survivors of critical illness: a prospective cohort study.

Egger M, Finsterhölzl M, Farabegoli D, Wippenbeck F, Schlutt M, Müller F, Huge V, Jahn K, Bergmann J.

2024-11-261 citations

10.1186/s13613-024-01396-x

Balance function in critical illness survivors and evaluation of psychometric properties of the Mini-BESTest.

Egger M, Finsterhölzl M, Buetikofer A, Wippenbeck F, Müller F, Jahn K, Bergmann J.

2024-05-276 citations

10.1038/s41598-024-61745-5

Outcome, predictors and longitudinal trajectories of subjects with critical illness polyneuropathy and myopathy (CINAMOPS): study protocol of an observational cohort study in a clinical and post-clinical setting

Jeannine Bergmann, Marion Egger, Friedemann Müller, Klaus Jahn

BMJ Open2024-04-015 citations

10.1136/bmjopen-2023-083553

Interventions

Group 1: Within the framework of the study, patients will be examined in complete five times during the first two years after disease onset. The first part of the study will be an electrophysiological

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: At least 5 days with invasive Ventilation at ICU, age = 18 years

Exclusion criteria

Exclusion criteria: Patients in palliative treatment. Neuromuscular or neurological diseases and/ or syndromes leading to a high-grade of muscular weakness: e.g. Guillain-Barré syndrome, myasthenia gravis, amyotrophic lateral sclerosis, cervical myelopathy, porphyria, Lambert-Eaton syndrome, severe vasculitic neuropathy, botulism. Insufficient communicative ability (knowledge of the German language, cognition), which make the execution of the assessments impossible (additionally no relative or legal guardian available as compensation), full motor strength (MRC 5/5) – no paralysis present.

Design outcomes

Primary

Measure	Time frame
• Description of the clinical and post-clinical course of disease in patients with CIP/CIM in comparison to patients with ICUAW without a proven CIP/CIM. • Evaluation of possible prognosis parameters for the medium- and long-term outcomes self-sufficiency, functioning & impairment and quality of life (12, 18 and 24 months after disease onset) of patients with CIP/CIM. • Investigation of the influence of the pre-clinical health status and frailty on the course of rehabilitation of patients with CIP/CIM.	—

Measure

Time frame

• Description of the clinical and post-clinical course of disease in patients with CIP/CIM in comparison to patients with ICUAW without a proven CIP/CIM. • Evaluation of possible prognosis parameters for the medium- and long-term outcomes self-sufficiency, functioning & impairment and quality of life (12, 18 and 24 months after disease onset) of patients with CIP/CIM. • Investigation of the influence of the pre-clinical health status and frailty on the course of rehabilitation of patients with CIP/CIM.

—

Secondary

Measure	Time frame
• Examination of robot-assisted therapies in patients with CIP/CIM • Evaluation of psychometric properties (reliability, validity) of the Mini-BESTest in patients with CIP/CIM • Evaluation of practicability and usability of the new approach for the electrophysiological testing • Evaluation of the clinical course and outcome in the subgroup of patients with CIP/CIM after SARS-CoV-19 infection	—

Measure

Time frame

• Examination of robot-assisted therapies in patients with CIP/CIM • Evaluation of psychometric properties (reliability, validity) of the Mini-BESTest in patients with CIP/CIM • Evaluation of practicability and usability of the new approach for the electrophysiological testing • Evaluation of the clinical course and outcome in the subgroup of patients with CIP/CIM after SARS-CoV-19 infection

—

Countries

Germany

Contacts

Public ContactMarion Egger

Schön Klinik Bad Aibling Harthausen

megger@schoen-klinik.de08061 / 903 1954

Outcome results

None listed